研究目的
To address the limitations of current CTC isolation platforms by introducing a patterned, immunofunctional, photodegradable poly(ethylene glycol) (PEG) hydrogel capture surface for the isolation and selective release of rare cell populations, aiming for improved CTC purity and viability.
研究成果
The photodegradable PEG hydrogel capture platform successfully combines enhanced capture efficiency with selective release capabilities, offering a promising approach for isolating pure and viable CTCs from complex media. This platform's ability to maintain cell viability and function post-release supports its potential for downstream CTC analysis and personalized cancer therapies.
研究不足
The study primarily focuses on model CTCs (A549 cells) and may require validation with patient-derived CTCs. The scalability of the hydrogel fabrication and cell release processes for clinical applications needs further investigation.
1:Experimental Design and Method Selection:
Utilized photopolymerizable and photodegradable PEG hydrogels for cell capture surfaces, combining immunoaffinity capture with reliable, cytocompatible, and on-demand cell release.
2:Sample Selection and Data Sources:
Human lung carcinoma cells (A549 cells) were used as model CTCs, captured from buffer, buffy coat, and whole blood.
3:List of Experimental Equipment and Materials:
Included PEGdiPDA, PEG monoacrylate, LAP photoinitiator, acryl-biotin, PDMS molds, and microfluidic devices.
4:Experimental Procedures and Operational Workflow:
Fabricated flat and herringbone patterned hydrogel surfaces via PDMS micromolding and photopolymerization, functionalized surfaces with anti-EpCAM antibodies, and performed cell capture and release experiments under flow conditions.
5:Data Analysis Methods:
Capture efficiency, density, and purity were calculated from cell counts obtained via fluorescent microscopy and ImageJ analysis.
独家科研数据包,助您复现前沿成果,加速创新突破
获取完整内容